Dana-Farber Study Highlights the Need for Faster, More Accurate Diagnosis of Rare Cancer - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Dana-Farber Study Highlights the Need for Faster, More Accurate Diagnosis of Rare Cancer

A new study from Dana-Farber Cancer Institute finds that patients with NUT carcinoma (NC), an aggressive squamous cell lung or head and neck cancer, often face delays in diagnosis—delays that can prevent them from receiving the right treatment or joining clinical trials.

  • December 8, 2025

  • 3 min

Share

Original Source(s)

Dana-Farber Study Highlights the Need for Faster, More Accurate Diagnosis of Rare Cancer

  • December 8, 2025

Related Content

What Medicare Claims Tell Us About Cancer Disparities in American Indian and Alaska Native Peoples

Diagnostic interpretation of CFH expression in pan-cancer analyses: the importance of factor H–like 1 isoform resolution

Posterior fossa ependymoma: a comprehensive review of molecular classification, management guidelines, and clinical outcomes (Part I of ependymomas across compartments)